ID   SNB-19
AC   CVCL_0535
SY   SNB.19; SNB19; Surgical Neurology Branch-19
DR   BTO; BTO:0003761
DR   CLO; CLO_0009093
DR   EFO; EFO_0002342
DR   MCCL; MCC:0000434
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ATCC; CRL-2219
DR   BioGRID_ORCS_Cell_line; 1486
DR   BioSample; SAMN03151977
DR   BioSample; SAMN03471000
DR   BioSample; SAMN03472567
DR   cancercelllines; CVCL_0535
DR   Cell_Model_Passport; SIDM00109
DR   ChEMBL-Cells; CHEMBL3307552
DR   ChEMBL-Targets; CHEMBL614164
DR   Cosmic; 875894
DR   Cosmic; 897439
DR   Cosmic; 905966
DR   Cosmic; 974241
DR   Cosmic; 1044249
DR   Cosmic; 1092637
DR   Cosmic; 1305361
DR   Cosmic; 1312343
DR   Cosmic; 1746950
DR   Cosmic; 1998480
DR   Cosmic; 2302333
DR   Cosmic; 2367548
DR   Cosmic; 2550361
DR   DepMap; ACH-001198
DR   DSMZ; ACC-325
DR   DSMZCellDive; ACC-325
DR   GEO; GSM2090
DR   GEO; GSM50178
DR   GEO; GSM50242
DR   GEO; GSM326246
DR   GEO; GSM743438
DR   GEO; GSM750785
DR   GEO; GSM799326
DR   GEO; GSM799389
DR   GEO; GSM847161
DR   GEO; GSM844697
DR   GEO; GSM887600
DR   GEO; GSM888683
DR   GEO; GSM1153396
DR   GEO; GSM1181304
DR   GEO; GSM1181321
DR   GEO; GSM2124686
DR   IARC_TP53; 2511
DR   IARC_TP53; 18084
DR   IGRhCellID; SNB19
DR   JCRB; NIHS0294
DR   LINCS_LDP; LCL-1363
DR   NCI-DTP; SNB-19
DR   PharmacoDB; SNB19_1429_2019
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   Progenetix; CVCL_0535
DR   PubChem_Cell_line; CVCL_0535
DR   SKY/M-FISH/CGH; 2822
DR   Wikidata; Q54955038
RX   CelloPub=CLPUB00261;
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RX   PubMed=2041050;
RX   PubMed=3121170;
RX   PubMed=3335022;
RX   PubMed=8528516;
RX   PubMed=10700174;
RX   PubMed=15748285;
RX   PubMed=17088437;
RX   PubMed=18304946;
RX   PubMed=19372543;
RX   PubMed=20143388;
RX   PubMed=20215515;
RX   PubMed=22068913;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22570425;
RX   PubMed=22628656;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24279929;
RX   PubMed=24335698;
RX   PubMed=24670534;
RX   PubMed=25877200;
RX   PubMed=27377824;
RX   PubMed=27807467;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://dtp.cancer.gov/discovery_development/nci-60/u251_snb-19.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=55
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-111.html
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a U-251MG derivative (PubMed=18304946; PubMed=20143388; PubMed=22570425). Originally thought to originate from a 47 year old patient with a left parieto-occipital glioblastoma.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: NCI-60 cancer cell line panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00268.
CC   Population: Caucasian.
CC   Doubling time: ~24 hours (DSMZ=ACC-325); 34.6 hours (NCI-DTP=SNB-19).
CC   HLA typing: A*02:01:01; B*18; C*05; DPB1*04:02; DQB1*02:01; DRB1*03:01:01 (PubMed=15748285).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Homozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=17088437).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.48%; Native American=0%; East Asian, North=2.88%; East Asian, South=0%; South Asian=0%; European, North=78.25%; European, South=18.39% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-2219; true.
CC   Discontinued: JCRB; NIHS0294; true.
CC   Derived from site: In situ; Brain, parietal lobe; UBERON=UBERON_0001872.
ST   Source(s): ATCC; DSMZ; PubMed=19372543; PubMed=25877200
ST   Amelogenin: X (PubMed=25877200)
ST   Amelogenin: X,Y (ATCC; DSMZ; PubMed=19372543)
ST   CSF1PO: 11,12 (ATCC; DSMZ; PubMed=25877200)
ST   CSF1PO: 12 (PubMed=19372543)
ST   D13S317: 10,11
ST   D16S539: 12
ST   D18S51: 13
ST   D19S433: 13,15
ST   D21S11: 29
ST   D2S1338: 22,24
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 10 (PubMed=19372543)
ST   D7S820: 10,12 (ATCC; DSMZ; PubMed=25877200)
ST   D8S1179: 13,15
ST   FGA: 21 (PubMed=19372543)
ST   FGA: 21,25 (DSMZ; PubMed=25877200)
ST   Penta D: 12
ST   Penta E: 7,10
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C60781; Astrocytoma
DI   ORDO; Orphanet_94; Astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0021 ! U-251MG
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 42
//
RX   CelloPub=CLPUB00261;
RA   Parker K.A., Pilkington G.J.;
RT   "Apoptosis of human malignant glioma-derived cell cultures treated
RT   with clomipramine hydrochloride, as detected by annexin-V assay.";
RL   Radiol. Oncol. 40:87-93(2006).
//
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RA   Nister M., Westermark B.;
RT   "Human glioma cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994).
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=3121170;
RA   Gross J.L., Behrens D.L., Mullins D.E., Kornblith P.L., Dexter D.L.;
RT   "Plasminogen activator and inhibitor activity in human glioma cells
RT   and modulation by sodium butyrate.";
RL   Cancer Res. 48:291-296(1988).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=8528516; DOI=10.1007/BF02634314;
RA   Welch W.C., Morrison R.S., Gross J.L., Gollin S.M., Kitson R.B.,
RA   Goldfarb R.H., Giuliano K.A., Bradley M.K., Kornblith P.L.;
RT   "Morphologic, immunologic, biochemical, and cytogenetic
RT   characteristics of the human glioblastoma-derived cell line, SNB-19.";
RL   In Vitro Cell. Dev. Biol. Anim. 31:610-616(1995).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=18304946; DOI=10.1093/nar/gkn089;
RA   Demichelis F., Greulich H., Macoska J.A., Beroukhim R., Sellers W.R.,
RA   Garraway L.A., Rubin M.A.;
RT   "SNP panel identification assay (SPIA): a genetic-based assay for the
RT   identification of cell lines.";
RL   Nucleic Acids Res. 36:2446-2456(2008).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24335698; DOI=10.1093/neuonc/not202;
RA   An Q., Fillmore H.L., Vouri M., Pilkington G.J.;
RT   "Brain tumor cell line authentication, an efficient alternative to
RT   capillary electrophoresis by using a microfluidics-based system.";
RL   Neuro-oncol. 16:265-273(2014).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//